2.15

0.46% -0.02

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Why PHIO Down? Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $2.15, with a volume of 100.16K. It is down -0.46% in the last 24 hours and up +23.43% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Previous Close:

$2.17

Open:

$2.27

24h Volume:

100.16K

Relative Volume:

0.03

Market Cap:

$12.24M

Revenue:

Net Income/Loss:

$-11.66M

P/E Ratio:

-0.2636

EPS:

-8.156

Net Cash Flow:

$-11.09M

1W Performance:

-8.47%

1M Performance:

+23.43%

6M Performance:

+3.35%

1Y Performance:

-65.72%

1-Day Range:

$2.15

$2.27

1-Week Range:

$2.11

$2.36

52-Week Range:

$0.9657

$9.79

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1171)

Industry

Biotechnology (661)

Phone

(508) 767-3861

Address

11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2024-11-07

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	2.16	12.24M	0	-11.66M	-11.09M	-8.156
VRTX Vertex Pharmaceuticals Inc	443.06	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	517.38	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	320.44	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	559.36	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	263.70	28.51B	3.81B	-644.79M	-669.77M	-6.24

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

Jun 12, 2025

Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes - TipRanks

Jun 12, 2025

Phio Pharmaceuticals Appoints Lisa Carson As Principal Financial OfficerSEC Filing - marketscreener.com

Jun 12, 2025

Jun 09, 2025

Research Analysts Set Expectations for PHIO FY2025 Earnings - Defense World

Jun 09, 2025

Jun 07, 2025

What is HC Wainwright’s Forecast for PHIO Q2 Earnings? - Defense World

Jun 07, 2025

Jun 06, 2025

Phio Pharmaceuticals appoints new strategic and finance VPs By Investing.com - Investing.com South Africa

Jun 06, 2025

Phio Pharmaceuticals appoints new strategic and finance VPs - Investing.com India

Jun 06, 2025

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - TradingView

Jun 06, 2025

Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan

Jun 06, 2025

Phio Pharmaceuticals (NASDAQ:PHIO) Now Covered by HC Wainwright - Defense World

Jun 06, 2025

Jun 05, 2025

Phio Pharma (PHIO) Receives Buy Rating and $14 Price Target from HC Wainwright | PHIO Stock News - GuruFocus

Jun 05, 2025

H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating - Investing.com India

Jun 05, 2025

Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Pr - GuruFocus

Jun 05, 2025

Jun 03, 2025

2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - The Globe and Mail

Jun 03, 2025

Jun 02, 2025

Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World

May 23, 2025

May 19, 2025

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile

May 19, 2025

Phio Reveals Latest Progress on Revolutionary Cancer-Fighting siRNA Technology at Investor Conference - Stock Titan

May 19, 2025

May 15, 2025

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile

May 15, 2025

May 09, 2025

Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX

May 09, 2025

May 07, 2025

Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks

May 07, 2025

Phio reports positive results in skin cancer trial - Investing.com

May 07, 2025

Phio reports positive results in skin cancer trial By Investing.com - Investing.com India

May 07, 2025

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile

May 07, 2025

May 01, 2025

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile

May 01, 2025

Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World

May 01, 2025

Apr 30, 2025

Elon Musk Could Bring Nvidia Stock $20 Billion Worth of Good News - The Globe and Mail

Apr 30, 2025

Apr 24, 2025

Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts

Apr 24, 2025

Apr 23, 2025

Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister

Apr 23, 2025

Best Momentum Stocks to Buy for April 23rd - TradingView

Apr 23, 2025

Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX

Apr 23, 2025

Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX

Apr 23, 2025

Apr 22, 2025

Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com

Apr 22, 2025